Table 3.
Polymer component a) | Molecular weight | Preparation method | Average size [nm] | Zeta potential [mV] | Cation to RNA ratio | Design elements | Experimental application | Outcome b) | Refs. |
---|---|---|---|---|---|---|---|---|---|
PEG‐P(Asp(DET)) | 22 kDa | Self‐assembly in 10 × 10‐3 m HEPES buffer | 50 | Not reported | N/P = 8 | Endosomal escape | Intrathecal | Expression in central nervous system | [94a] |
PEG‐P(Asp(DET)) P(DMAEMA‐co‐OEGMA) |
22 kDa 54 kDa |
Self‐assembly in 10 × 10‐3 m HEPES buffer Self‐assembly in 10 × 10‐3 m HEPES buffer (pH 7.3) |
Not reported |
Not reported 0.071 ± 0.159 |
N/P = 3 | N/P = 3 | Intranasal | Local expression | [100] |
50 | N/P = 3 | N/P = 3 | Hydrodynamic injection | Liver | [101] | ||||
Self‐assembly in 10 × 10‐3 m HEPES buffer (pH 7.3) Self‐assembly in 10 × 10‐3 m HEPES buffer (pH 7.4) |
50 65 ± 5 |
N/P = 8 | N/P = 8 | Intra‐articular | Local expression | [102] | |||
Not reported | N/P = 3 | N/P = 3 | Intracerebral | Genome editing in brain | [103] | ||||
Self‐assembly in 10 × 10‐3 m HEPES buffer (pH 7.4) Self‐assembly in HEPES buffered saline (HBS, 150 × 10‐3 m NaCl, 10 × 10‐3 m HEPES, pH 7.4) |
Not reported |
Not reported 37 ± 15 |
N/P = 3 | N/P = 3 | Intraspinal injections | Spinal cord injury treatment | [104] | ||
20–22 kDa | 37 | N/P 10–40 | PEGylation | Intracellular | BEAS‐2B cells | [105] | |||
PEGMA‐p(DMAEMA‐co‐BMA)) | 61.7 kDa | Self‐assembly in nuclease‐free water | 86 ± 16 | 12.4 ± 0.7 | N/P = 3 | Endosomal escape | Intracellular | T cells | [106] |
P(MEO3MA)‐b‐P(H2N‐Cys‐MA) | 69.3 kDa | Self‐assembly in 10 × 10‐3 m HEPES buffer (pH 7.4) | 87 | Not reported | N/P = 5 | Redox‐responsive by disulfide bonds | Intracellular | RAW macrophages and 3T3 fibroblasts | [107] |
P(EtOx)‐P(EI) | 45 kDa for mRNA, and 72 kDa | Self‐assembly in DMEM | 80–450 | −5–2 | 7000 (molar ratio) | Molar mass and charge density optimized | Intracellular | HEK 293T cells | [81] |
PEG‐P(Asp(TEP))‐Chol | 34 kDa | Self‐assembly in 10 × 10‐3 m HEPES buffer (pH 7.3) | 55 | Not reported | N/P = 8 | Hydrophobicity and endosomal escape | i.v. | BxPC‐3 pancreatic tumor | [110] |
PEG‐P(Asp(DET))‐Chol | 25 kDa | Self‐assembly in 10 × 10‐3 m HEPES buffer (pH 7.4) | 60–65 | 1.1 | N/P = 3 | Chol (+)‐OligoRNA | Intratracheal | Local expression | [112a] |
PEG‐PLys | 19 kDa |
Self‐assembly in 10 × 10‐3 m HEPES buffer (pH 7.4) Mixing polymer solution (10 × 10‐3 m HEPES buffer, pH 3.5) with mRNA solution (10 × 10‐3 m HEPES buffer, pH 7.4) |
100 | Not reported | N/P = 2 | mRNA bundling | Intracerebral |
Improved blood circulation Local expression |
[112b] |
PEG‐PGBA | 22 kDa | 56 | 1.1 | N/P = 3 | Flexible polycation | Intranasal |
Improved blood circulation; Local expression |
[115] | |
PEG‐PGMG | 18 kDa | 62 | 0.90 | N/P = 3 | Multivalent interactions from guanidine | Intracellular | HuH‐7 cells | [116] | |
PEG‐PGTyr | 26 kDa | 75 | Not reported | N/P = 3 | π–π stacking | i.v. and i.m. |
Improved blood circulation Local expression |
[117] | |
cRGD‐PEG/PNIPAM‐PLys(SH) | 12 kDa/5 kDa | 59 ± 2 | 1.89 ± 0.28 | N/P = 1.5 | Redox‐responsive crosslinking; thermo‐responsive | i.v. | U‐87 glioma tumor | [119] | |
PEG‐PLys(AMP) | 23 kDa | 53 ± 2 | −1.23 ± 0.4 | N/P = 2 | Redox‐responsive crosslinking | Intracellular | HuH‐7 cells | [120] | |
PEG‐PAsp(DET/FPBA)‐Chol, PEG‐PAsp(DET/GlcAm)‐Chol | 22 kDa | 70–90 | −2.5 ± 0.9 | N/P = 1.5 | ATP‐responsive crosslinking; Chol (+)‐OligoRNA | Intracellular | Improved blood circulation | [112c] | |
PEG‐pLL(CAA) | 20 kDa | 94 ± 1 | Not reported | Not reported | pH‐responsive crosslinking | Intratumoral | Improved expression in CT 26 tumors | [123] | |
PEG‐PAsp(DET/FPBA) | 24 kDa | 59–72 | Not reported | N/P = 1.5 | ATP‐responsive crosslinking | Intratracheal | Local expression | [112d] |
The full name of polymers can be found in the main text;
BEAS‐2B: human non‐tumorigenic lung epithelial cell line; 3T3: mouse embryonic fibroblast cell line, HEK 293T: a stable clone derivative of the human embryonic kidney (HEK) 293 cell line; HuH‐7: hepatocyte‐derived carcinoma cell line.